Class Action Lawsuit Announced for Regencell Bioscience Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy RGC?
Source: Globenewswire
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, indicating significant legal risks that may undermine shareholder confidence.
- Compensation Structure: Investors may receive compensation without any out-of-pocket costs through a contingency fee arrangement, which could encourage more affected investors to participate, thereby amplifying the lawsuit's impact.
- Legal Risks Exposed: The lawsuit alleges that Regencell failed to disclose vulnerabilities to market manipulation and the financial risks posed to investors during the class period, potentially leading to increased regulatory scrutiny that could adversely affect the company's market performance.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and credibility in handling similar cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGC
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regencell Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Regencell Bioscience Holdings Limited for violations of securities laws, involving trades from October 28, 2024, to October 31, 2025, potentially impacting investor rights.
- Market Manipulation Risk: The complaint alleges that Regencell made false and misleading public statements during this period, leading to significant stock volatility due to market manipulation, which increased the risk of regulatory scrutiny and reputational harm.
- Investor Losses: Following the revelation of the truth about Regencell, investors suffered damages, and the Schall Law Firm encourages affected shareholders to contact them before June 23, 2026, to participate in the lawsuit and seek compensation for their losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, allowing investors to reach out via phone or website to understand their rights and potential legal actions they can take.
See More
Class Action Lawsuit Announced for Regencell Bioscience Holdings
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, indicating significant legal risks that may undermine shareholder confidence.
- Compensation Structure: Investors may receive compensation without any out-of-pocket costs through a contingency fee arrangement, which could encourage more affected investors to participate, thereby amplifying the lawsuit's impact.
- Legal Risks Exposed: The lawsuit alleges that Regencell failed to disclose vulnerabilities to market manipulation and the financial risks posed to investors during the class period, potentially leading to increased regulatory scrutiny that could adversely affect the company's market performance.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and credibility in handling similar cases.
See More
Regencell Bioscience Class Action Reminder for Shareholders
- Class Action Initiated: Robbins LLP reminds all investors who purchased Regencell Bioscience Holdings Limited (NASDAQ:RGC) securities between October 28, 2024, and October 31, 2025, that a class action has been filed to protect shareholder rights and seek compensation.
- Market Manipulation Allegations: The complaint alleges that Regencell was impacted by market manipulation during this period, leading to significant volatility in its stock price, which exposed investors to substantial financial risks and was not disclosed in a timely manner, increasing regulatory and legal risks.
- Expected Legal Costs: Regencell disclosed in an SEC filing on October 31, 2025, that it received a subpoena from the U.S. Department of Justice due to market volatility, anticipating significant legal costs and potential fines, further exacerbating the company's financial strain.
- Stock Price Drop Impact: Following the disclosure, Regencell's ordinary share price fell by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025, indicating market uncertainty about the company's future and a decline in investor confidence.
See More
Regencell Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting serious concerns regarding the company's operations and compliance policies.
- Allegations of Misrepresentation: The lawsuit alleges that Regencell and its executives failed to disclose significant adverse facts related to the company's business, including vulnerabilities to market manipulation, which exposed investors to substantial financial risks and potential regulatory scrutiny.
- Investor Rights Protection: Affected investors are encouraged to apply by June 23, 2026, to be appointed as lead plaintiffs in the lawsuit, indicating the potential impact and importance of this case for investor rights.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights, securities, and commercial litigation, showcasing its expertise and experience in protecting investor interests.
See More
Regencell Faces Securities Class Action Lawsuit
- Lawsuit Background: A securities class action lawsuit has been filed in the U.S. District Court for Maryland on behalf of all investors who purchased Regencell (NASDAQ: RGC) securities between October 28, 2024, and October 31, 2025, alleging undisclosed market manipulation risks.
- Risk Disclosure: The complaint highlights that the volatility of Regencell's ordinary shares exposed investors to significant financial risks, and the failure to disclose these risks could lead to regulatory scrutiny and legal liabilities, impacting the company's reputation.
- Legal Consequences: Given that the defendants' public statements were deemed materially false and misleading during the relevant period, investors may face legal and financial losses, with the lawsuit potentially resulting in substantial damages for the company.
- Investor Action: Investors are urged to contact Gainey McKenna & Egleston law firm before the June 23, 2026, lead plaintiff motion deadline to ensure their rights are protected in the class action.
See More
Regencell Faces Class Action Lawsuit; Investors Encouraged to Join
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting concerns over potential legal risks and financial losses for investors.
- Allegations of False Statements: The complaint alleges that executives made materially false and misleading statements during the class period, failing to disclose the company's vulnerability to market manipulation, which exposed investors to significant financial risks, reflecting deficiencies in corporate governance and compliance policies.
- Increased Regulatory Risks: Due to the volatility faced by the company, the lawsuit indicates that Regencell may be subjected to heightened regulatory scrutiny and enforcement actions, potentially leading to significant legal, financial, and reputational harm, further impacting investor confidence.
- Investor Call to Action: Investors are encouraged to apply to be lead plaintiffs by June 23, 2026, to share in any potential recovery from the lawsuit, underscoring the case's significance and potential impact on investors.
See More
Regencell Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Regencell Bioscience Holdings Limited for violations of securities laws, involving trades from October 28, 2024, to October 31, 2025, potentially impacting investor rights.
- Market Manipulation Risk: The complaint alleges that Regencell made false and misleading public statements during this period, leading to significant stock volatility due to market manipulation, which increased the risk of regulatory scrutiny and reputational harm.
- Investor Losses: Following the revelation of the truth about Regencell, investors suffered damages, and the Schall Law Firm encourages affected shareholders to contact them before June 23, 2026, to participate in the lawsuit and seek compensation for their losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, allowing investors to reach out via phone or website to understand their rights and potential legal actions they can take.
See More
Class Action Lawsuit Announced for Regencell Bioscience Holdings
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, indicating significant legal risks that may undermine shareholder confidence.
- Compensation Structure: Investors may receive compensation without any out-of-pocket costs through a contingency fee arrangement, which could encourage more affected investors to participate, thereby amplifying the lawsuit's impact.
- Legal Risks Exposed: The lawsuit alleges that Regencell failed to disclose vulnerabilities to market manipulation and the financial risks posed to investors during the class period, potentially leading to increased regulatory scrutiny that could adversely affect the company's market performance.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and credibility in handling similar cases.
See More
Regencell Bioscience Class Action Reminder for Shareholders
- Class Action Initiated: Robbins LLP reminds all investors who purchased Regencell Bioscience Holdings Limited (NASDAQ:RGC) securities between October 28, 2024, and October 31, 2025, that a class action has been filed to protect shareholder rights and seek compensation.
- Market Manipulation Allegations: The complaint alleges that Regencell was impacted by market manipulation during this period, leading to significant volatility in its stock price, which exposed investors to substantial financial risks and was not disclosed in a timely manner, increasing regulatory and legal risks.
- Expected Legal Costs: Regencell disclosed in an SEC filing on October 31, 2025, that it received a subpoena from the U.S. Department of Justice due to market volatility, anticipating significant legal costs and potential fines, further exacerbating the company's financial strain.
- Stock Price Drop Impact: Following the disclosure, Regencell's ordinary share price fell by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025, indicating market uncertainty about the company's future and a decline in investor confidence.
See More
Regencell Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting serious concerns regarding the company's operations and compliance policies.
- Allegations of Misrepresentation: The lawsuit alleges that Regencell and its executives failed to disclose significant adverse facts related to the company's business, including vulnerabilities to market manipulation, which exposed investors to substantial financial risks and potential regulatory scrutiny.
- Investor Rights Protection: Affected investors are encouraged to apply by June 23, 2026, to be appointed as lead plaintiffs in the lawsuit, indicating the potential impact and importance of this case for investor rights.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights, securities, and commercial litigation, showcasing its expertise and experience in protecting investor interests.
See More
Regencell Faces Securities Class Action Lawsuit
- Lawsuit Background: A securities class action lawsuit has been filed in the U.S. District Court for Maryland on behalf of all investors who purchased Regencell (NASDAQ: RGC) securities between October 28, 2024, and October 31, 2025, alleging undisclosed market manipulation risks.
- Risk Disclosure: The complaint highlights that the volatility of Regencell's ordinary shares exposed investors to significant financial risks, and the failure to disclose these risks could lead to regulatory scrutiny and legal liabilities, impacting the company's reputation.
- Legal Consequences: Given that the defendants' public statements were deemed materially false and misleading during the relevant period, investors may face legal and financial losses, with the lawsuit potentially resulting in substantial damages for the company.
- Investor Action: Investors are urged to contact Gainey McKenna & Egleston law firm before the June 23, 2026, lead plaintiff motion deadline to ensure their rights are protected in the class action.
See More
Regencell Faces Class Action Lawsuit; Investors Encouraged to Join
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting concerns over potential legal risks and financial losses for investors.
- Allegations of False Statements: The complaint alleges that executives made materially false and misleading statements during the class period, failing to disclose the company's vulnerability to market manipulation, which exposed investors to significant financial risks, reflecting deficiencies in corporate governance and compliance policies.
- Increased Regulatory Risks: Due to the volatility faced by the company, the lawsuit indicates that Regencell may be subjected to heightened regulatory scrutiny and enforcement actions, potentially leading to significant legal, financial, and reputational harm, further impacting investor confidence.
- Investor Call to Action: Investors are encouraged to apply to be lead plaintiffs by June 23, 2026, to share in any potential recovery from the lawsuit, underscoring the case's significance and potential impact on investors.
See More
